Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (Nasdaq: ARTL) has announced promising preclinical results for its drug candidate ART12.11, a CBD:TMP cocrystal, in treating stress-induced depression. The data, presented at the 35th Annual International Cannabinoid Research Society Symposium, demonstrates the drug's effectiveness comparable to sertraline (Zoloft) in treating depression-related behaviors.

Key findings show that ART12.11's 28-day treatment significantly improved depression-related behaviors in male rats, including restoration of hedonic and social behaviors. Notably, ART12.11 showed superior cognitive benefits compared to sertraline, successfully reversing stress-induced deficits in spatial and short-term memory without negative impacts on social memory.

Artelo Biosciences (Nasdaq: ARTL) has announced positive results from its first-in-human Phase 1 Single Ascending Dose (SAD) study of ART26.12, a novel non-opioid pain treatment candidate. The study, involving 49 subjects, demonstrated favorable safety and pharmacokinetic profiles for the first orally active Fatty Acid Binding Protein 5 (FABP5) inhibitor tested in humans.

Key findings from the study include excellent safety results with only mild, transient, and self-resolving adverse events, predictable pharmacokinetics with dose-dependent linear absorption, and a wide safety margin between therapeutic plasma concentrations and highest exposure levels. The drug represents a first-in-class approach targeting the multibillion-dollar pain management market.

The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is projected to surpass $159 billion by 2030. A Multiple Ascending Dose study is planned to commence in Q4 2025 to further evaluate ART26.12's safety, tolerability, and pharmacokinetics with repeated dosing.

Artelo Biosciences (Nasdaq: ARTL) has secured a $1.425 million At-the-Market private placement financing through a definitive securities purchase agreement. The company will issue 136,844 shares of common stock and 93,179 pre-funded warrants, along with warrants to purchase additional shares at $5.82 and $10.00 per share.

The funding will support the announcement of clinical data from two phase 1 studies for ART26.12 and a phase 2 study readout from the CAReS trial for ART27.13. Notably, $250,000 of the net proceeds will be allocated to purchase SOL digital currency, with the remaining funds used for general corporate purposes.

Artelo Biosciences (NASDAQ: ARTL) has announced a 6-for-1 reverse stock split effective June 13, 2025, approved by its Board of Directors on May 20, 2025. The clinical-stage pharmaceutical company, which focuses on lipid-signaling pathway modulation for cancer, pain, and neurological treatments, implemented this split to meet Nasdaq's minimum $1.00 per share closing bid price requirement for continued listing. Following the reverse split, every six shares will automatically convert into one share, reducing outstanding shares to approximately 546,667. The company's warrants and derivatives will automatically adjust to reflect the split, while shareholders' pro-rata ownership percentages remain unchanged. Trading under the new CUSIP number 04301G607 will commence at market open on June 13.

Artelo Biosciences presented promising new data for its FABP5 inhibitor ART26.12 at the British Pain Conference, showing favorable comparison to naproxen in treating osteoarthritis pain. In a surgical rat model study, ART26.12 demonstrated dose-responsive analgesic effects that were sustained over 28 days, improving weight-bearing ability in affected limbs. The drug candidate, currently in human trials, is being developed as a non-opioid, non-steroidal treatment for chemotherapy-induced peripheral neuropathy and potentially chronic osteoarthritis pain. ART26.12's effectiveness matched naproxen, a first-line therapy known for serious side effects with chronic use. This development is significant given that osteoarthritis affects 606.9 million people globally, including 32 million in the U.S., causing chronic pain, reduced mobility, and decreased quality of life.

Artelo Biosciences (NASDAQ: ARTL) highlights a new independent review paper published in Neurobiology of Disease that validates their FABP inhibitor program for anxiety and depression treatment. The paper, co-authored by Dr. Steven Laviolette and researchers from the University of Western Ontario, provides evidence that FABP5, FABP3, and FABP7 are crucial in regulating lipid trafficking and neuroinflammatory signaling. Artelo's clinical-stage candidate ART26.12, which targets FABP5, has completed enrollment in a Phase 1 Single Ascending Dose study with nearly 50 healthy volunteers. The company expects to announce data this quarter and results from a food effect study this summer. The research suggests that FABP5 inhibition can increase anandamide levels and produce anxiety-reducing and antidepressant effects without typical cognitive side effects.

Artelo Biosciences (NASDAQ: ARTL) reported its Q1 2025 financial results and provided updates on its clinical pipeline. The company highlighted progress across three key programs: ART26.12, the first selective FABP5 inhibitor in clinical trials, completed Phase I enrollment with data expected in Q2 2025; ART27.13's Phase 2 CAReS study in cancer anorexia-cachexia syndrome with initial data expected in Q3 2025; and ART12.11, a proprietary cannabidiol cocrystal tablet showing improved pharmacokinetics versus Epidiolex®.

Financial results showed R&D expenses of $1.4M (vs $1.5M in Q1 2024), G&A expenses of $1.0M (vs $1.1M), and a net loss of $2.4M ($0.72 per share). Cash position stood at $0.7M, with an additional $0.9M raised through convertible notes in May 2025.

Artelo Biosciences (Nasdaq: ARTL) has published new research in the Journal of Investigative Dermatology demonstrating the effectiveness of ART26.12, their FABP5 inhibitor, in treating psoriasis. The study shows that ART26.12, an orally active small-molecule drug, achieved comparable results to immunomodulatory drugs in both in vitro and in vivo psoriasis models.

The research highlights that FABP5, first discovered in psoriasis tissue in the 1990s, is highly expressed in skin and immune cells and plays a important role in skin cell homeostasis. Pre-clinical studies suggest ART26.12 may offer a less costly and safer treatment approach for psoriasis compared to existing options.

The company has completed enrollment for its Phase 1 Single Ascending Dose study of ART26.12 in healthy volunteers, with data expected to be announced in the current quarter.

Artelo Biosciences (NASDAQ: ARTL) has announced that Lead Medicinal Chemist Myles Osborn will present at the 4th ACE Drug Discovery Summit in London on April 3, 2025. The presentation, scheduled for 12:30pm BST, will focus on analyzing multiple datasets regarding Fatty Acid Binding Protein 5 (FABP5) inhibition across various disease models.

The presentation, titled 'Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,' will explore how FABP5 inhibition affects cellular communication pathways. Research has shown promising activity in treating neuropathic pain, osteoarthritis, cancer, and cancer bone pain.

The company's lead FABP5 inhibitor, ART26.12, is currently in Phase 1 Single Ascending Dose study with healthy volunteers, with data expected in Q2 2025.